𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole

✍ Scribed by Orencio Bosch; Gloria Moraleda; Inmaculada Castillo; Vicente Carreño

Book ID
118566410
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
345 KB
Volume
19
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis C with ci
Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha
✍ Margarita Pardo; Inmaculada Castillo; Sonia Navas; Dr. Vicente Carreño 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 525 KB

Interferon therapy in cirrhotic patients with hepatitis C virus infection is not efficient. In an at- tempt t o improve the response rate, a pilot study using recombinant human granulocyte colonystimulating factor (rhG-CSF) alone, and in combination with recombinant interferon-alpha (rlFN), was carr

Therapy of chronic hepatitis b with reco
Therapy of chronic hepatitis b with recombinant human alpha and gamma interferon
✍ Adrian M. Di Bisceglie; Vinod K. Rustgi; Chris Kassianides; Mauricio Lisker-Melm 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 584 KB

Eight patients with chronic hepatitis B entered a pilot study of gamma interferon and alpha interferon in combination. Gamma interferon alone had minimal inhibitory effects on serum levels of hepatitis B virus as monitored by serum HBV DNA and DNA-polymerase activity. The drug also gave troublesome

Recombinant leukocyte interferon treatme
Recombinant leukocyte interferon treatment of chronic hepatitis B
✍ Geoffrey Dusheiko; Adrian Dibisceglie; Sheila Bowyer; Evelyn Sachs; Marian Ritch 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 513 KB

We have investigated the efficacy of a relatively prolonged course of recombinant leukocyte interferon treatment in 14 chronic HBsAg-, HBeAg-, hepatitis B virus DNA-and DNA polymerasepositive carriers. a-Interferon was administered for 9 weeks. Six of 14 treated carriers have a sustained loss of HBe